JP2022516347A5 - - Google Patents

Info

Publication number
JP2022516347A5
JP2022516347A5 JP2021539364A JP2021539364A JP2022516347A5 JP 2022516347 A5 JP2022516347 A5 JP 2022516347A5 JP 2021539364 A JP2021539364 A JP 2021539364A JP 2021539364 A JP2021539364 A JP 2021539364A JP 2022516347 A5 JP2022516347 A5 JP 2022516347A5
Authority
JP
Japan
Application number
JP2021539364A
Other languages
Japanese (ja)
Other versions
JPWO2020141495A5 (https=
JP2022516347A (ja
JP7548911B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/050063 external-priority patent/WO2020141495A1/en
Publication of JP2022516347A publication Critical patent/JP2022516347A/ja
Publication of JPWO2020141495A5 publication Critical patent/JPWO2020141495A5/ja
Publication of JP2022516347A5 publication Critical patent/JP2022516347A5/ja
Application granted granted Critical
Publication of JP7548911B2 publication Critical patent/JP7548911B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021539364A 2019-01-04 2020-01-06 腫瘍性疾患の治療のためのカプセル化グリコリピド抗原 Active JP7548911B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788257P 2019-01-04 2019-01-04
US62/788,257 2019-01-04
PCT/IB2020/050063 WO2020141495A1 (en) 2019-01-04 2020-01-06 Encapsulated glycolipid antigens for treatment of neoplastic diseases

Publications (4)

Publication Number Publication Date
JP2022516347A JP2022516347A (ja) 2022-02-25
JPWO2020141495A5 JPWO2020141495A5 (https=) 2022-11-02
JP2022516347A5 true JP2022516347A5 (https=) 2022-11-02
JP7548911B2 JP7548911B2 (ja) 2024-09-10

Family

ID=71407387

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539364A Active JP7548911B2 (ja) 2019-01-04 2020-01-06 腫瘍性疾患の治療のためのカプセル化グリコリピド抗原

Country Status (8)

Country Link
US (1) US12337033B2 (https=)
EP (1) EP3906053A4 (https=)
JP (1) JP7548911B2 (https=)
CN (1) CN113507936A (https=)
AU (1) AU2020205040A1 (https=)
CA (1) CA3125702A1 (https=)
SG (1) SG11202107306WA (https=)
WO (1) WO2020141495A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999444B (zh) * 2014-10-03 2023-12-12 安吉尼科分子传输公司 完整的细菌衍生的囊泡对小分子化合物的增强装载
CN121285390A (zh) * 2023-04-17 2026-01-06 安吉尼科分子传输公司 用于递送α-半乳糖神经酰胺化合物的组合物和方法
EP4656648A1 (en) * 2024-05-31 2025-12-03 Consejo Superior De Investigaciones Científicas Immunomodulatory thiourea and urea carbohydrate compounds and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747002B2 (en) 1999-05-11 2004-06-08 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
ATE541940T1 (de) 2001-10-15 2012-02-15 Engeneic Molecular Delivery Pty Ltd Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo
CA2517027A1 (en) 2002-02-25 2003-09-04 Vaxiion Therapeutics, Inc. Minicell compositions and methods
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
CN101954095B (zh) 2003-12-09 2013-03-13 基因分子传递股份有限公司 通过源自细菌的完整小细胞将靶基因递送至非吞噬哺乳动物细胞
EP1718338B1 (en) 2004-02-02 2015-05-06 EnGeneIC Molecular Delivery Pty Ltd. Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
EP2386640B1 (en) 2004-08-26 2015-01-28 EnGeneIC Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
US9878043B2 (en) 2006-06-23 2018-01-30 Engeneic Molecular Delivery Pty Ltd Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
DK2865755T3 (en) 2007-03-30 2017-05-15 Engeneic Molecular Delivery Pty Ltd BACTERIAL DERIVATIVE INTACT MINICELLS WITH REGULATORY RNA
ES2720659T3 (es) 2011-02-15 2019-07-23 Vaxiion Therapeutics Llc Composiciones terapéuticas y métodos para la administración dirigida, mediante minicélulas bacterianas, de moléculas bioactivas basadas en moléculas dirigidas que contienen Fc y anticuerpos
EP3692794A1 (en) 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
US8591963B2 (en) 2011-10-06 2013-11-26 Jose Luis MENDOZA Direct application pet odor eliminator
US9365496B2 (en) 2011-11-30 2016-06-14 Ludwig Institute For Cancer Research iNKT cell modulators and methods of using the same
US20150283235A1 (en) 2012-11-05 2015-10-08 Regimmune Corporation Immune-tolerance inducer
SG11201602429QA (en) 2013-10-04 2016-04-28 Engeneic Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
WO2015116775A1 (en) 2014-01-30 2015-08-06 Trudeau Institute Nanoparticles for immune stimulation
US11167008B2 (en) 2016-11-23 2021-11-09 Vaxiion Therapeutics, Llc Immunomodulatory and oncolytic minicells and methods of use
JP2021532106A (ja) 2018-07-23 2021-11-25 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 細菌由来ミニ細胞を含む組成物およびそれを使用する方法

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)